| Trial ID: | L5306 |
| Source ID: | NCT02796170
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02796170/results
|
| Conditions: |
Type 2 Diabetes|Hypertension
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM, Blood pressure was measured at baseline with a 24 hour ambulatory blood pressure machine (ABPM), and again after 6 weeks of treatment., Baseline to 6 weeks | Secondary: Change in Urinary AGT Levels From Baseline to 6 Weeks, Urinary Angiotensinogen (AGT) was measured through the collection of 24 hour urine at baseline and again after 6 weeks of treatment. Angiotensinogen was normalized to creatinine., Baseline to 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: Tulane University School of Medicine | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
11
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-03
|
| Completion Date: |
2020-08
|
| Results First Posted: |
2022-11-01
|
| Last Update Posted: |
2022-11-01
|
| Locations: |
Tulane University, New Orleans, Louisiana, 70112, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02796170
|
